This review is a summary of the ACTIVATE study, which investigated the effect of aclidinium bromide/
eformoterol fumarate 400/12 μg bronchodilator therapy on lung hyperinflation, exercise capacity and physical
activity, with and without behavioural intervention, in patients with moderate-to-severe COPD.
Independent commentary is provided by Dr Christopher Worsnop, a respiratory and sleep physician at the Austin Hospital in Melbourne. Dr Worsnop is a Fellow of the Royal Australasian College of Physicians, and chairs the Respiratory Special Interest Group of the Australasian Sleep Association, and is vice-chair of the TSANZ COPD special interest group.
Please login below to download this issue (PDF)